Why Pathology Labs Are Under More Pressure Than Ever — And What Actually Fixes It
If you run a pathology lab, you already know the demand problem isn't coming. It's here.
Cancer incidence keeps climbing. Molecular and companion-diagnostic testing keeps expanding. Reimbursement is finally catching up to digital pathology. By every demand signal that matters, this should be a straightforward growth story for pathology labs across North America.
It isn't, though — because growth is colliding with a capacity problem most labs are managing quietly, one open req and one overtime shift at a time.
This isn't a diagnostic skill issue. It's a throughput issue: the people, instruments, and workflows required to get a specimen from collection to a signed-out report. And for most labs, the place where that throughput actually breaks down isn't where the budget conversation usually starts.
Let's walk through why pathology demand is rising, where the real bottlenecks sit, and what's actually changing in how labs work with their equipment and consumables partners.
Why Demand for Pathology Services Keeps Rising
Three forces are driving specimen volume higher across hospital, academic, and reference pathology labs — and none of them are slowing down.
Rising Cancer Burden
An aging population combined with higher cancer incidence is driving sustained growth in tissue-based diagnostic volume. This is the single biggest demand driver for histology and anatomic pathology services, and it isn't a temporary spike — it's a multi-year trend that shows up in specimen counts, not just headlines.
Precision Medicine and Molecular Diagnostics
Molecular pathology and spatial biology platforms are expanding what a single tissue sample can tell a clinician. Companion diagnostics, biomarker panels, and genomic testing all depend on tissue that's been properly fixed, processed, and sectioned upstream.
That's worth sitting with for a second: more advanced downstream testing means more pressure on the same histology workflow, not less. Precision medicine doesn't bypass the histology lab. It depends on it.
Digital Pathology Is Becoming Standard Infrastructure
For years, regulatory and reimbursement uncertainty gave labs a reason to delay digital pathology investment. That excuse is largely gone.
FDA clearances for whole-slide imaging platforms closed a long-standing compliance gap between 2017 and 2024. In 2024, CMS introduced CPT code 88360, adding a dedicated reimbursement pathway for digital pathology consultation. And in one of the more closely watched moves in the space, a major national reference lab partnered with a leading scanner manufacturer in 2025 to deploy FDA-cleared whole-slide imaging across its anatomic pathology service line — a clear signal that scale players are no longer waiting on the sidelines.
Market estimates vary by methodology, but the direction is consistent: North America accounts for somewhere between roughly 37% and 48% of global digital pathology revenue, and that share is still growing.
The takeaway: Pathology demand isn't a forecast anymore. It's a current operating condition. The question for lab leaders isn't whether volume will keep rising — it's whether workflow capacity can keep pace with it.
The Biggest Challenges Pathology Labs Face Right Now
Ask any histology manager or lab director what's keeping them up at night, and you'll hear a consistent list.
Staffing Shortages That Aren't Closing on Their Own
The pathologist and histotechnologist pipeline is under real strain. Workforce projections point to a meaningful U.S. pathologist shortfall by the late 2030s, and a significant share of the current pathologist workforce is approaching retirement age within the next several years. Histotechnologist vacancy rates sit in the high single digits nationally — a number that sounds modest until you're the lab director trying to fill the third open req this year.
Every unfilled seat pushes more volume onto the people still on staff. That accelerates burnout. Burnout accelerates the next departure. It's a compounding problem, not a static one.
Turnaround Time Pressure
Staffing gaps and equipment downtime rarely show up on a budget line first. They show up as a slower turnaround time. For oncology cases especially, that delay has real consequences — for treatment planning, for patient anxiety, and for how much confidence referring physicians have in your lab.
Equipment Downtime That Costs More Than It Looks
A single tissue processor or slide stainer going down doesn't just stop one machine. It stops every case queued behind it. Without a service relationship built for fast response, a routine repair can turn into a multi-day backlog that takes weeks to fully clear.
Procurement Complexity
As labs add digital pathology, molecular platforms, and automated systems on top of traditional histology equipment, sourcing decisions get more complicated. More brands. More service contracts. More points of failure. Procurement teams that used to handle straightforward purchase orders are now being pulled into conversations that used to belong purely to the bench.
Cost Pressure and Reimbursement Lag
Labs are absorbing rising consumable and labor costs while reimbursement structures — even with welcome additions like CPT 88360 — evolve more slowly than operating costs do. That gap has to be made up somewhere, and it's rarely through headcount growth.
Why Histology Is Still the Biggest Bottleneck in Pathology Workflow
Here's the uncomfortable truth behind a lot of digital pathology investment: none of it matters if the tissue itself isn't processed, embedded, sectioned, and stained correctly and on time.
Histology is the physical choke point that every downstream innovation — AI-assisted diagnostics, whole-slide imaging, molecular testing — ultimately depends on. You can have the best scanner on the market, and it won't fix a turnaround-time problem that starts three steps earlier, at the grossing bench.
Here's where operational risk actually concentrates across the histology workflow:
Grossing. Inconsistent specimen description and missed tissue lead to pathologist rework, repeat cases, and liability exposure. Standardized protocols and adequate grossing station capacity are the fix — not more downstream automation.
Processing. Instrument downtime here halts the entire case queue behind it. Idle staff time, overnight run failures, and reagent waste follow quickly. This is where reliable tissue processors and fast vendor support matter most.
Embedding. A manual bottleneck during high-volume periods, and one that drives real technician fatigue. Overtime costs climb, and quality starts to vary between staff. Ergonomic embedding stations and cross-trained coverage help absorb the volume spikes.
Sectioning. Highly skill-dependent, and the stage where the histotechnologist shortage hits hardest. Slide quality issues here drive re-cuts and pathologist queries — well-maintained microtomes and cryostats, plus structured technician training, are the lever.
Staining. Stain inconsistency across runs directly affects diagnostic confidence. Automated slide stainers with tight QC and consistent reagent lots reduce the repeat work that inconsistency creates.
Imaging and Reporting. Scanner throughput and IT integration gaps slow case completion and create bottlenecked digital consults. Scanner capacity planning and LIS/digital workflow integration are what close this gap.
The pattern worth remembering: The labs seeing real turnaround-time improvement are the ones treating histology infrastructure and digital infrastructure as one connected investment — not two separate budget lines.
Technology Trends Reshaping Pathology Right Now
A few real shifts are changing what "good lab operations" looks like.
Digital pathology is moving from pilot to infrastructure. With FDA-cleared scanners and a CMS reimbursement code now in place, whole-slide imaging is becoming a standard line item in capital planning — sitting alongside cryostats and tissue processors, not replacing them.
AI-assisted diagnostics are arriving as decision support, not replacement. Image-analysis software for tasks like biomarker scoring and companion-diagnostic quantification is maturing quickly, particularly in oncology. The realistic near-term role isn't replacing pathologists — it's reducing the manual scoring burden so a constrained workforce can read out more cases per day.
Pathology automation is shifting from "nice to have" to operational necessity. With staffing gaps unlikely to close through hiring alone, labs are looking at automated stainers, processors, and slide-management systems less as efficiency upgrades and more as the only realistic way to hold turnaround times steady as volume grows.
Procurement is becoming a strategic function. As labs layer digital, molecular, and automated systems onto traditional histology equipment, sourcing decisions get more complex. Procurement teams are now part of conversations that used to live entirely on the bench.
What Pathology Labs Now Need From Equipment & Consumables Suppliers
Talk to enough lab directors and a clear pattern emerges: the relationship labs want with their suppliers has fundamentally changed. A purchase order and a price list used to be enough. It isn't anymore.
Here's what comes up again and again in conversations with histology managers and procurement leads:
- Equipment reliability — not just on spec sheets, but in real uptime across processors, stainers, and cryostats running daily, high-volume caseloads.
- Responsive technical support — a service relationship that can troubleshoot or dispatch quickly, because every hour of downtime queues up cases behind it.
- Real training, not just a manual — onboarding that gets new histotechs productive faster, in a labor market where experienced staff are hard to find and harder to keep.
- Consumable consistency — lot-to-lot reliability on reagents and stains, because variability shows up downstream as repeat work and diagnostic uncertainty.
- Multi-brand procurement support — a single point of contact who can source across instrument and consumable brands, instead of five separate vendor relationships.
- Supply chain resilience — backup sourcing and inventory planning that protects turnaround time when any single supplier hits a disruption.
What labs are really asking for: Not another vendor. A partner who treats the lab's turnaround-time problem as a shared problem — not just a sales opportunity.
Where BP LabLine Fits Into This Picture
BP LabLine works with pathology and histology labs across New England and beyond on exactly the problem outlined above: keeping workflows running reliably without adding unsustainable cost or complexity.
In practice, that looks like curated sourcing across histology instrumentation — cryostats, microtomes, tissue processors, and slide stainers — selected for reliability in real lab conditions, not just spec-sheet performance. It means consistent pathology consumables supply, so reagent and staining variability isn't adding noise to an already strained workflow. And it means workflow-level consultation that starts by identifying where a lab's actual bottleneck sits — often upstream of where the budget conversation starts — before recommending any equipment at all.
For hospital systems, universities, biotech companies, and CROs navigating increasingly complex purchasing requirements, that also means multi-brand, flexible sourcing: one accountable point of contact instead of five separate vendor relationships to manage.
The goal isn't to sell labs more equipment. It's to help them build operations resilient enough to absorb the next staffing gap, the next volume spike, or the next supply disruption — without it becoming a patient-facing problem.
The Bottom Line
Digital pathology investment and histology workflow investment aren't competing budget lines. They're one connected system, and the labs that treat them that way are the ones seeing real turnaround-time improvement.
A few questions worth raising at your next lab or budget meeting:
- Where does your actual turnaround-time bottleneck sit — and is it upstream of where you'd expect?
- Do you have backup sourcing for critical reagents and consumables, or are you exposed to a single point of failure?
- Are you evaluating supplier service response time and training support as seriously as you evaluate instrument specs?
- Are digital pathology and histology automation investments being planned together, or as separate initiatives?
The labs that come out ahead over the next few years won't necessarily be the ones with the newest scanner. They'll be the ones that fixed their workflow foundation first.
Frequently Asked Questions
What is the biggest bottleneck in pathology lab workflow? Histology remains the biggest bottleneck for most pathology labs. Even with strong digital pathology and AI tools in place, turnaround time depends on how efficiently a lab handles grossing, processing, embedding, sectioning, and staining — the upstream stages that every downstream diagnostic step depends on.
Why is there a pathologist and histotechnologist shortage? A combination of retirements among the current pathologist workforce, limited training-program capacity, and rising specimen volume from cancer incidence and expanded molecular testing has created a sustained gap between workforce supply and diagnostic demand across North America.
Does digital pathology replace the need for histology equipment? No. Digital pathology and AI-assisted diagnostics depend on tissue that has already been properly processed, embedded, sectioned, and stained. Whole-slide scanners optimize the reporting and review stage — they don't reduce the need for reliable cryostats, microtomes, tissue processors, and slide stainers upstream.
How can a pathology lab reduce turnaround time? Most turnaround-time gains come from identifying which histology stage is actually creating delay — often grossing or processing, not imaging — and addressing it with the right combination of equipment reliability, staffing support, and standardized protocols, rather than assuming a new scanner or software tool will solve it.
What should pathology labs look for in an equipment and consumables supplier? Beyond price and specs, labs increasingly evaluate suppliers on real-world equipment reliability, responsive technical support, hands-on staff training, lot-to-lot consumable consistency, and supply chain resilience — since any one of these gaps can directly affect diagnostic turnaround time.
